PFZW investments in listed companies that have been selected for both their societal and financial returns perform relatively better than the broader index, Martin Eijgenhuijsen and Dirk-Jan Verzuu conclude.
How does a patient benefit from the use of a new medicine? Does he live longer, does quality of life improve relatively? And does the new drug contribute to the affordability of our care system? Martin Eijgenhuijsen reflects on an impact project.
PGGM has received the results of two impact measurement projects that we’ve set up with two pharmaceutical companies. These data can help us to become a better impact investor, writes Martin Eijgenhuijsen.
